Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas

Table 2

Selected clinical characteristics of the study subjects, stratified according to NRAS mutation status.

(a)

NRAS mutation	Death				Fisher test
	No		Yes
	N	%	N	%
Negative	11	100%	0	0%	0.0833
Positive	0	0%	1	100%

(b)

NRAS mutation	Histological type				Fisher test
	Borderline		Serous
	N	%	N	%
Negative	7	100%	4	80%	0.4167
Positive	0	0%	1	20%

(c)

NRAS mutation	FIGO stage				Fisher test
	IA		Other
	N	%	N	%
Negative	7	100%	4	80%	0.4167
Positive	0	0%	1	20%

No significant relationships were found between NRAS mutation status, mortality, histological type, and FIGO stage of the tumor.